Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 11/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019956 | 0.89 | POLB (0.67) | ADRA1DADRA1AADRA1BPOLBESR2 | |
| SCHEMBL8367125 | 0.80 | POLB (0.75) | ADRA1DADRA1AADRA1BPOLBESR2 | |
| SCHEMBL18358970 | 0.80 | POLB (0.75) | ADRA1DADRA1AADRA1BPOLBESR2 | |
| SCHEMBL6104980 | 0.79 | CA2 (0.51) | ADRA1DADRA1AADRA1BPOLBESR2 | |
| SCHEMBL1021052 | 0.77 | ADRA1A (0.47) | ADRA1DADRA1AADRA1BCA2HTR1A | |
| SCHEMBL6974656 | 0.77 | ADRA1A (0.47) | ADRA1DADRA1AADRA1BCA2HTR1A | |
| SCHEMBL14367867 | 0.77 | ADRA1D (0.53) | ADRA1DADRA1AADRA1BCA2HTR1A | |
| SCHEMBL14367882 | 0.77 | ADRA1D (0.53) | ADRA1DADRA1AADRA1BCA2HTR1A | |
| SCHEMBL4961831 | 0.76 | ADRA1D (0.47) | ADRA1DADRA1AADRA1BPOLBESR2 | |
| SCHEMBL1885058 | 0.76 | CA2 (0.40) | ADRA1DADRA1AADRA1BPOLBESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271634-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-02-12 | — | — | EP | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2271634-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133107-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | ADRA1D 30/4885ADRA1A 45/4885ADRA1B 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.